Period6 May 2020

Media coverage

1

Media coverage

  • TitleFirst Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Australian Stock Exchange:MSB.AX
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    Country/TerritoryJordan
    Date6/05/20
    PersonsAlan Moskowitz, Emilia Bagiella, Annetine Gelijns